Endoscopic Treatment for Barrett’s Esophagus with Low-Grade Dysplasia

Barrett’s esophagus develops when long-term reflux damages the normal lining of the lower esophagus and causes it to resemble intestinal tissue. In some people, this altered lining develops low-grade dysplasia, meaning early cellular changes that may increase the risk of esophageal adenocarcinoma.

Endoscopic therapy can remove or destroy abnormal tissue before invasive cancer develops. Treatment decisions depend on expert pathology review, the appearance and size of any visible lesion, the length of the Barrett’s segment, reflux control and the patient’s overall health.

These issues were relevant to the scientific programme of the 17th World Congress for Esophageal Diseases, held virtually from 27–30 September 2021 by the International Society for Diseases of the Esophagus. Its sessions, workshops and research presentations highlighted the importance of careful staging, specialist expertise and long-term surveillance.

Why Low-Grade Dysplasia Requires Careful Assessment

A diagnosis of low-grade dysplasia is not always straightforward. Inflammation from reflux can produce changes that resemble dysplasia, and different pathologists may interpret the same biopsy differently. A second review by a gastrointestinal pathologist is therefore an important safety step before treatment.

The risk is also influenced by visible abnormalities. A flat area of confirmed dysplasia may be suitable for ablation, while a nodule, ulcer or irregular lesion usually requires endoscopic resection so that the tissue can be examined fully. Any suspicion of invasive cancer changes the management pathway.

Confirming the Diagnosis and Mapping the Segment

High-definition gastroscopy, often with virtual or dye-based chromoendoscopy, helps identify subtle mucosal changes. Targeted biopsies are taken from suspicious areas, while systematic biopsies document the remaining Barrett’s segment. The endoscopist also records the length and distribution of the metaplasia.

For patients in Australia, assessment commonly occurs through a tertiary public hospital or a private specialist service in cities such as Sydney, Melbourne, Brisbane, Perth or Adelaide. Referral to a unit with advanced endoscopy and upper gastrointestinal pathology is especially valuable when the original diagnosis is uncertain or treatment is being considered.

How Endoscopic Therapy Works

Visible lesions are generally treated first with endoscopic mucosal resection or endoscopic submucosal dissection in selected cases. These techniques remove abnormal tissue rather than simply destroying it, allowing the pathologist to assess depth, margins and other features that indicate cancer risk.

For residual flat Barrett’s mucosa with confirmed dysplasia, radiofrequency ablation is commonly used. It applies controlled thermal energy to the abnormal surface, which later heals and is replaced by squamous lining. Cryotherapy may be considered when radiofrequency treatment is unsuitable or has not achieved adequate clearance. Acid suppression, usually with a proton pump inhibitor, supports healing and reflux control.

Balancing Treatment Benefits and Risks

Eradicating dysplastic Barrett’s tissue can reduce progression to high-grade dysplasia and cancer, but endoscopic therapy is not risk-free. Temporary chest discomfort, swallowing pain, bleeding and narrowing of the esophagus can occur. Stricture risk is higher when large areas are treated or repeated sessions are needed.

Surveillance alone may be reasonable for carefully selected patients after expert review, particularly where dysplasia is very limited, uncertain or not confirmed on repeat examination. The decision should account for age, comorbidities, procedural risk, cancer risk and the patient’s ability to attend repeated appointments.

The Australian Care Pathway

Australia’s public and private systems can offer advanced endoscopic treatment, although access varies between metropolitan centres and regional or remote areas. A patient from northern Queensland, Western Australia or rural New South Wales may need travel, accommodation and coordinated follow-up in a specialist centre.

Costs depend on the setting, physician fees, anaesthesia, pathology, hospital cover and the number of treatment sessions. Medicare arrangements and private health insurance do not remove every out-of-pocket expense, so written estimates are useful. Therapeutic devices and medicines are also subject to Australian regulation, including oversight by the Therapeutic Goods Administration.

Lifestyle factors remain relevant. Reflux may be aggravated by large evening meals, excess alcohol, smoking, obesity and lying down soon after eating. These habits are common targets for practical change, alongside prescribed acid suppression.

Practical Points for Safer Treatment and Follow-Up

• Obtain confirmation of low-grade dysplasia from an experienced gastrointestinal pathologist.
• Ask whether all visible lesions need resection before any ablation is performed.
• Choose an endoscopist and hospital familiar with Barrett’s eradication therapy.
• Use prescribed proton pump inhibitor treatment and report persistent reflux or swallowing difficulty.
• Plan for several appointments when radiofrequency ablation or cryotherapy is required.
• Keep every surveillance endoscopy appointment, even when symptoms have improved.
• Discuss Medicare, private insurance, pathology and travel costs before treatment begins.

Successful management is measured by durable clearance of dysplasia and metaplastic tissue, not simply by one uncomplicated procedure. Recurrent Barrett’s changes can occur, so surveillance remains necessary after apparent eradication.

For an Australian patient, the practical takeaway is to secure expert pathology review, receive treatment in an experienced upper gastrointestinal endoscopy service, control reflux consistently and maintain the scheduled surveillance plan.